Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 4/2012

01-12-2012 | Interstitial Lung Disease (G Tino, Section Editor)

Connective tissue disease-associated interstitial lung disease: a review

Authors: Markus Gutsche, Glenn D. Rosen, Jeffrey J. Swigris

Published in: Current Pulmonology Reports | Issue 4/2012

Login to get access

Abstract

Interstitial lung disease (ILD) is commonly encountered in patients with connective tissue diseases (CTD). Besides the lung parenchyma, the airways, pulmonary vasculature and structures of the chest wall may all be involved, depending on the type of CTD. As a result of this so-called multi-compartment involvement, airflow limitation, pulmonary hypertension, vasculitis and extrapulmonary restriction can occur alongside fibro-inflammatory parenchymal abnormalities in CTD. Rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Sjögren’s syndrome (SjS), systemic lupus erythematosus (SLE), and undifferentiated connective tissue disease (UCTD), as well as mixed connective tissue disease (MCTD), can all be associated with the development of ILD. Nonspecific interstitial pneumonia (NSIP) is the most commonly observed histopathological pattern in CTD-ILD, but other patterns, including usual interstitial pneumonia (UIP), organizing pneumonia (OP), diffuse alveolar damage (DAD) and lymphocytic interstitial pneumonia (LIP), may occur. Although the majority of patients with CTD-ILD experience stable or slowly advancing ILD, a small yet significant group exhibits a more severe and progressive course. Randomized placebo-controlled trials evaluating the efficacy of immunomodulatory treatments have been conducted only in SSc-associated ILD. However, clinical experience suggests that a handful of immunosuppressive medications are potentially effective in a sizeable portion of patients with ILD caused by other CTDs. In this manuscript, we review the clinical characteristics and management of the most common CTD-ILDs.
Literature
1.
•• Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010;138(2):251–6. A synopsis and discussion of “lung-dominant connective tissue diseases”, “autoimmune-featured ILD” and “undifferentiated connective tissue diseases” including a proposal for criteria to more accurately capture the group of “lung-dominant CTDs”. PubMedCrossRef
2.
Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140(5):1292–9.PubMedCrossRef
3.
Homma Y, Ohtsuka Y, Tanimura K, Kusaka H, Munakata M, Kawakami Y, Ogasawara H. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration. 1995;62(5):248.PubMedCrossRef
4.
•• Wells AU. Pulmonary function tests in connective tissue disease. Semin Respir Crit Care Med. 2007;28:379–88. Excellent summary on pulmonary function test patterns observed in CTD-ILD. PubMedCrossRef
5.
Lee H, Kim DS, Yoo B, Seo JB, Rho J, Colby TV, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019–27.PubMedCrossRef
6.
• Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232:81–91. Description of characteristic HRCT-patterns in patients with RA-related ILD. PubMedCrossRef
7.
Song JW, Do K, Kim M, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009;136:23–30.PubMedCrossRef
8.
Park JH, Kim DS, Park I, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705–11.PubMedCrossRef
9.
Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322–8.PubMedCrossRef
10.
•• King TE Jr, Kim EJ, Kinder BW. Connective tissue diseases. In: King TE, Schwartz M, editors. Interstitial lung disease. 5th ed; 2011. Detailed review of connective tissue disease – related interstitial lung diseases from standard reference textbook for the interstitial lung diseases.
11.
Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. 2002;22:S151–65.PubMedCrossRef
12.
•• Hwang JH, Misumi S, Sahin H, et al. Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr. 2009;33:410–5. Comprehensive reviews of radiologic and histopathologic features in CTD-ILD. PubMedCrossRef
13.
•• Lynch DA. Lung disease related to collagen vascular disease. J Thoracic Imaging. 2009;24(4):299–309. Excellent overview of radiologic, serologic and histopathologic patterns of lung injury from CTD. CrossRef
14.
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–66.PubMedCrossRef
15.
Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–70.PubMedCrossRef
16.
Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009 May;337(5):329–35.PubMedCrossRef
17.
Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well-tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130:30–6.PubMedCrossRef
18.
Kobayashi A, Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol. 2012;5(2):219–27.PubMedCrossRef
19.
Hyland RH, Gordon DA, Broder I, Davies GM, Russell ML, Hutcheon MA, et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J Rheumatol. 1983;10:395–405.PubMed
20.
Jurik AG, Davidsen D, Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol. 1982;11:217–24.PubMedCrossRef
21.
Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, Lake FR. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156:528–35.PubMed
22.
Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis. 1997;56:463–9.PubMedCrossRef
23.
Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010;36(2):213–41.PubMedCrossRef
24.
Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis. 1994;53:434–9.PubMedCrossRef
25.
Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol. 2005;15:173–9.PubMedCrossRef
26.
Scott DL, Bradby GV, Aitman TJ, Zaphiropoulos GC, Hawkins CF. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann Rheum Dis. 1981;40:136–41.PubMedCrossRef
27.
Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J. 2002;19:756–64.PubMedCrossRef
28.
Thavarajah K, Wu P, Rhew EJ, Yeldandi AK, Kamp DW. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med. 2009;103:661–9.PubMedCrossRef
29.
•• pneumotox.com – Foucher P, Camus P. The drug-induced lung diseases. Very useful online tool that allows searches for individual medications listing all respective drug-induced pulmonary complications described in the literature.
30.
Abel T, Andrews BS, Cunningham PH, et al. Rheumatoid vasculitis: Effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med. 1980;93:407–13.PubMed
31.
Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: A case report. J Korean Med Sci. 2002;17:270–3.PubMed
32.
Scott DGI, Bacon PA. Resonse to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax. 1980;35:725–31.PubMedCrossRef
33.
• Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998;17:48–54. A comprehensive review of the general clinical features of systemic sclerosis. PubMedCrossRef
34.
Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60:1831–9.PubMedCrossRef
35.
• Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49:399–412. This article is part of a series on immunologic testing guidelines published by the American College of Rheumatology and HOC Committee on Immunologic Testin. For further details an introduction to this series has been published in Arthritis Care and Research, Vol 47, Nr 4, August 2002 pp 429 –433. PubMedCrossRef
36.
Bouros D, Wells AU, Nicholson AG, Cobly TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–6.PubMedCrossRef
37.
Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–54.PubMedCrossRef
38.
Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41:1835–44.PubMedCrossRef
39.
Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026–34.PubMedCrossRef
40.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.PubMedCrossRef
41.
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7. Original description and diagnostic criteria for polymyositis and dermatomyositis by Bohan and Peter. PubMedCrossRef
42.
Krain L. Dermatomyositis in six patients without initial muscle involvement. Arch Dermatol. 1975;111:241–5.PubMedCrossRef
43.
• Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med. 2007;28:451–8. A comprehensive review of polymyositis and dermatomyositis with emphasis on the pulmonary manifestation. PubMedCrossRef
44.
• Ikezoe J, Johkoh T, Kohno N, et al. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis. J Thorac Imag. 1996;11:250–9. A review of radiological features on chest HRCT in PM/DM. CrossRef
45.
46.
Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis/dermatomyositis. Respir Med. 2007;101:1761–9.PubMedCrossRef
47.
Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois RM, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44:585–96.PubMedCrossRef
48.
Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22:245–50.PubMedCrossRef
49.
Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182–5.PubMed
50.
Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32:273–84.PubMedCrossRef
51.
Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26:459–67.PubMedCrossRef
52.
Chen I, Jan Wu Y, Lin C, Fan K, Luo S, Ho H. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28:639–46.PubMedCrossRef
53.
• Dalakas M, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82. A comprehensive review of the general clinical features of polymyositis and dermatomyositis. PubMedCrossRef
54.
Evans J. Antinuclear antibody testing in systemic autoimmune disease. Clin Chest Med. 1998;19:613–25. vii.PubMedCrossRef
55.
Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol. 1993;100:116S–23.PubMedCrossRef
56.
Marie I, Hachulla E, Chérin P, Dominique S, Hatron P, Hellot M, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614–22.PubMedCrossRef
57.
Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol. 1998;25:1336–43.PubMed
58.
Selva-O’Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, Martínez-Gomez X, Majó-Masferrer J, Solans-Laque R, et al. Polymyositis/dermatomyositis associated lung disease: analysis of a series of 81 patients. Lupus. 2005;14:534–42.PubMedCrossRef
59.
Imbert-Masseau A, Hamidou M, Agard C, Grolleau JY, Chérin P. Antisynthetase syndrome. Joint Bone Spine. 2003;70:161–8.PubMedCrossRef
60.
Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka R, Ito T, Nureki S, Kumamoto T. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol. 2010;29(4):443–5.PubMedCrossRef
61.
Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, Miyasaka N. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005;23(5):707–10.PubMed
62.
Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, Kurihara Y, Osada H, Satoh M, Ozaki S. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124.CrossRef
63.
Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719.PubMed
64.
Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48:968–71.CrossRef
65.
Lambotte O, Kotb R, Maigne G, Blanc F, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369–70.PubMed
66.
Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201.PubMedCrossRef
67.
Sjögren H. Zur Kenntnis der keratoconjunctivitis sicca. Acta Ophthalomol. 1933;11(suppl II):1.
68.
• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American –European Consensus Group. Ann Rheum Dis. 2002;61:554–8. Diagnostic criteria for primary and secondary Sjögren’s syndrome following revision by the European Study Group on Classification Criteria for Sjögren’s syndrome. PubMedCrossRef
69.
Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjögren’s syndrome. Medicine (Baltimore). 1982;61:247–57.
70.
Carine S, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X. Anticentromere antibodies identify patients with Sjögren’s syndrome and autoimmune overlap syndrome. J Rheumatol. 2007;34:2253–8.
71.
Fischbach M, Char D, Christensen M, et al. Immune complexes in Sjögren’s syndrome. Arthritis Rheum. 1980;23:791–5.PubMedCrossRef
72.
• Fox R. Sjögren’s syndrome. Lancet. 2005;366:321–31. A comprehensive review of the general clinical features of Sjögren’s syndrome. PubMedCrossRef
73.
Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al. Lymphomas in patients with Sjögren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90:766–75.PubMed
74.
Papathanasiou MP, Constantopoulos SH, Tsampoulas C, Drosos AA, Moutsopoulos HM. Reappraisal of respiratory abnormalities in primary and secondary Sjögren’s syndrome. A controlled study. Chest. 1986;90:370–4.PubMedCrossRef
75.
Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210–9.CrossRef
76.
Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjögren’s syndrome. A clinical, functional, and histologic study. Chest. 1985;88:226–9.PubMedCrossRef
77.
• Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjögren’s syndrome. Clin Chest Med. 1998;19:687–99. viii. A comprehensive review of the pleuro-pulmonary manifestations of SjS. PubMedCrossRef
78.
Launay D, Hachulla E, Hatron P, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86:299–315.CrossRef
79.
Chen H, Lai S, Kwang W, Liu J, Chen C, Huang D. Middle lobe syndrome as the pulmonary manifestation of primary Sjögren’s syndrome. Med J Aust. 2006;184:294–5.PubMed
80.
Tavoni A, Vitali C, Cirigliano G, Frigelli S, Stampacchia G, Bombardieri S. Shrinking lung in primary Sjögren’s syndrome. Arthritis Rheum. 1999;42:2249–50.PubMedCrossRef
81.
• Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. Chest. 2006;130:1489–95. A comprehensive overview of interstitial lung diseases in SjS. PubMedCrossRef
82.
Yamadori I, Fujita J, Bandoh S, Tokuda M, Tanimoto Y, Kataoka M, et al. Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjögren’s syndrome. Rheumatol Int. 2002;22:89–92.PubMedCrossRef
83.
Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63 Suppl 5:v1–58.PubMed
84.
Devaraj A, Wells AU, Hansell DM. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med. 2007;28:389–97.PubMedCrossRef
85.
Koyama M, Johkoh T, Honda O, Mihara N, Kozuka T, Tomiyama N, et al. Pulmonary involvement in primary Sjögren’s syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging. 2001;16:290–6.PubMedCrossRef
86.
• Honda O, Johkoh T, Ichikado K, Tomiyama N, Maeda M, Mihara N, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. AJR Am J Roentgenol. 1999;173:71–4. An interesting study comparing HRCT-findings of lymphocytic interstitial pneumonia and malignant lymphoma of the chest to delineate the differentiating features of these two disorders. PubMed
87.
88.
• Mosca M, Tani C, Neri C, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev. 2006;6(1):1. Description of “undifferentiated connective tissue diseases” as a distinct disease entity. PubMedCrossRef
89.
• Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148. Original description of “mixed connective tissue disease” as a separate disease entity by Sharp et al. PubMedCrossRef
90.
Bodolay E, Szekanecz Z, Dévényi K, Galuska L, Csípo I, Vègh J, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005;44:656–61.CrossRef
91.
• Prakash UB. Respiratory complications in mixed connective tissue disease. Clin Chest Med. 1998;19:733–46. ix. A comprehensive review of MCTD-related pulmonary complications. PubMedCrossRef
92.
Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA, Maltby JD, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984;63:92–107.
93.
Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56:2092–4.PubMedCrossRef
94.
Swaak AJ, Nossent JC, Smeenk RJ. Systemic lupus erythematosus. Int J Clin Lab Res. 1992;22:190–5.PubMedCrossRef
95.
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113–24.
96.
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7. Revised Criteria for the diagnosis of SLE from the Subcommittee for Systemic Lupus Erythematosus Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. PubMedCrossRef
97.
Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol. 1996;166:301–7.PubMed
98.
• Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol. 2009;23:469–80. Concise review of the pulmonary manifestations in SLE. PubMedCrossRef
99.
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999;78:167–75.CrossRef
100.
Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35:248–54.PubMedCrossRef
101.
Bankier AA, Kiener HP, Wiesmayr MN, Fleischmann D, Kontrus M, Herold CJ, et al. Discrete lung involvement in systemic lupus erythematosus: CT assessment. Radiology. 1995;196:835–40.PubMed
102.
Sant SM, Doran M, Fenelon HM, Breatnach ES. Pleuropulmonary abnormalities in patients with systemic lupus erythematosus: assessment with high resolution computed tomography, chest radiography and pulmonary function tests. Clin Exp Rheumatol. 1997;15:507–13.PubMed
103.
Matthay RA, Schwarz MI, Petty TL, Stanford RE, Gupta RC, Sahn SA, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore). 1975;54:397–409.CrossRef
104.
Colby TV. Pulmonary pathology in patients with systemic autoimmune diseases. Clin Chest Med. 1998;19:587–612. vii.PubMedCrossRef
105.
Min JK, Hong YS, Park SH, Park JH, Lee SH, Lee YS, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in patients with systemic lupus erythematosus. J Rheumatol. 1997;24:2254–7.PubMed
106.
Filipek MS, Thompson ME, Wang P, Gosselin MV, Primack LS. Lymphocytic interstitial pneumonitis in a patient with systemic lupus erythematosus: radiographic and high-resolution CT findings. J Thorac Imaging. 2004;19:200–3.PubMedCrossRef
107.
Carette S, Macher AM, Nussbaum A, Plotz PH. Severe, acute pulmonary disease in patients with systemic lupus erythematosus: ten years of experience at the National Institutes of Health. Semin Arthritis Rheum. 1984;14:52–9.PubMedCrossRef
108.
Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore). 1997;76:192–202.CrossRef
109.
Todd DJ, Costenbader KH. Dyspnoea in a young woman with active systemic lupus erythematosus. Lupus. 2009;18:777–84.PubMedCrossRef
Metadata
Title
Connective tissue disease-associated interstitial lung disease: a review
Authors
Markus Gutsche
Glenn D. Rosen
Jeffrey J. Swigris
Publication date
01-12-2012
Publisher
Current Science Inc.
Published in
Current Pulmonology Reports / Issue 4/2012
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-012-0028-7

Other articles of this Issue 4/2012

Current Pulmonology Reports 4/2012 Go to the issue

Interstitial Lung Disease (G Tino, Section Editor)

Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going

Asthma (S Peters and J Oppenheimer, Section Editors)

Asthma clinical trials of American Lung Association/Asthma Clinical Research Centers (ALA-ACRC): what have we learned in 12 years?

Asthma (S Peters and J Oppenheimer, Section Editors)

Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort

Asthma (S Peters and J Oppenheimer, Section Editors)

The Childhood Asthma Management Program (CAMP): contributions to the understanding of therapy and the natural history of childhood asthma

Interstitial Lung Disease (G Tino, Section Editor)

Non-pharmacological treatment of idiopathic pulmonary fibrosis

Interstitial Lung Disease (G Tino, Section Editor)

Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits